Loading
Latest filing published 26 Aug 2022 for Vincerx Pharma, Inc., €30k. Read the official filing
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
Filings by Christopher P. Lowe span 2 companies, the busiest being IRulya Therapeutics Inc. and Vincerx Pharma, Inc. We count 7 filings; the first trade dates from 28 June 2021 and the latest from 24 August 2022.
On the market, this insider has only ever bought: 2 purchases, €98k in total. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. The rest of the record consists of 1 share grant and 4 option exercises. So far in 2022, the count stands at 1 purchase and no sales.
On 26 August 2022 came the latest disclosure, an open-market purchase for €30k in Vincerx Pharma, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. For comparison, the SEC allows two business days to file a Form 4. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
7 of 7 declarations